Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05409027 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62
A Phase 1 study, sponsored by Sparrow Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05409027 is a Phase 1 study that has completed, run by Sparrow Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT05409027, a Phase 1 study, has completed, sponsored by Sparrow Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)
Interventions
- DRUG SPI-62
- DRUG Cortisone-d8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-07-23 |
| Est. Completion | 2024-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05409027
The ClinicalTrials.gov registry entry for NCT05409027 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sparrow Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SPI-62 is the first listed.
NCT05409027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05409027 about?
NCT05409027 is a clinical study titled "A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62". This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)
What is the current status of trial NCT05409027?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-07-23. Estimated completion is 2024-02-07.
What interventions are being tested in trial NCT05409027?
The interventions under investigation include: SPI-62 (DRUG), Cortisone-d8 (DRUG).
Who is sponsoring clinical trial NCT05409027?
This trial is sponsored by Sparrow Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.